


Herring Milt: A Potential Functional Ingredient for Obesity and Type-2 Diabetes

Yanwen Wang, PhD
Senior Research Officer (NRC)
Jacques Gagnon, PhD
Senior Research Scientist (VALORĒS)

NCE Blue Legasea Webinar
May 27, 2021

Metabolic syndrome



<https://www.metabolicsyndromecanada.ca/about-metabolic-syndrome>

Key facts

- Heart disease has remained the number one cause of death globally for the last 20 years. The number of deaths increased by > 2 million since 2000 to nearly 9 million in 2019.
- Currently, more than 1 billion adults are overweight – of which at least 300 million are clinically obese.
- Childhood obesity is already epidemic in some areas and on the rise in others.
- Deaths from diabetes increased by 70% globally between 2000 and 2019.



WHO, 2020

Valorization of marine biomass and marine-based by-products

- Collection, preservation and processing
- Extraction and fractionation
- Chemical analysis/characterization
- In vitro cell based assays
 - **Glucose-stimulated insulin release in pancreatic beta cells**
 - Glucose uptake in peripheral tissues (muscle, fat cells)
 - Anti-obesity activity
 - Anti-inflammation
 - Antioxidant activity
 - Neuroprotection/ anti-ageing

In vitro screening of marine-based extracts for glucose-stimulated insulin secretion

- INS-1E rat insulinoma cells were used as the *in vitro* assay model.
- Cytotoxicity was measured using the MTT assay.
- Extracts were screened for glucose stimulated insulin secretion (GSIS) using ELISA kit.
- 82 extracts/samples were tested.



The 1st screening

The first screening conditions

- 3 doses (10, 50, 100 µg/mL) of each product
- GSIS at 25 mM of glucose

Results

- 10 : Toxic, not tested
- 38 : 0- 20% of increase
- 32 : $\geq 20\%$ of increase
- 2 : Toxic, but have $\geq 20\%$ of increase

The 2nd screening

Screening conditions

32 candidates (>20% increase of GSIS) were tested at 2 doses (50, 100 µg/ml)
GSIS at 5.5, 11, and 25 mM of glucose, respectively
40% increase of GSIS was set as the cut-off.

Results

Number of Sample	≥ 40 % increase in insulin secretion	Number of Sample	≥ 40 % increase in insulin secretion
1	1-2W	8	1-5 W
2	1-5A	9	1-5 H
3	1-5 M	10	3-2 W
4	2-1 P+ A	11	3-3 R
5	2-4 M	12	3-3 f [®]
6	1-4 f [®]	13	5-3 P
7	1-4 R		

The 3rd screening on fractionation prepared from the lead candidates in the 2nd screening

Sample code	Origin	Form
YW-0046	Shrimp oil	Liquid
1-2 W	Sea cucumber - internal organs	Dry powder
1-5 W	Sea cucumber - dry flower	Dry powder
1-5 H	Sea cucumber - dry flower	Dry powder
1-5 A	Sea cucumber - dry flower	Dry powder
1-5 M	Sea cucumber - dry flower	Dry powder
2-1 P+A	Herring - milt / hydrolysis	Dry powder
3-2 W	Crab - hepatopancreas	Dry powder
5-3 P	Sardine - cutting / hydrolysis	Dry powder

Preparation of herring milt protein hydrolysate (HPH)



HPH ← ^{Bioreactor} _{Alcalase} Herring milt


Protein	Lipids	EPA	DHA	Arginine
70.8	10.8	8.0	10.8	29

Diet composition


Ingredient#	LFC	HFC	HPH15	HPH35	HPH70
<i>Diet composition</i>					
Casein (80 Mesh)	200	200	170	130	60
L-Cystine	3	3	3	3	3
Corn Starch	315	0	0	0	0
Maltodextrin 10	35	125	125	125	125
Sucrose	350	68.8	68.8	68.8	68.8
Herring Milt Hydrolysate	0	0.00	42.4	98.9	197.7
Cellulose, BW200	50	50	50	50	50
Lard (96%)	20	245	240.4	234.3	223.6
Soybean Oil	25	25	25	25	25
Mineral Mix S10026	10	10	10	10	10
DiCalcium Phosphate	13	13	13	13	13
Calcium Carbonate	5.5	5.5	5.5	5.5	5.5
Potassium Citrate, 1 H2O	16.5	16.5	16.5	16.5	16.5
Vitamin Mix V10001	10	10	10	10	10
Choline Bitartrate	2	2	2	2	2
FD&C Blue Dye 1	0.05	0.05	0.05	0.05	0.05
Total (g)	1055	774	782	792	810
<i>Calorie information</i>					
Protein (% kcal)	20	20	20	20	20
Fat (% kcal)	10	60	60	60	60
Carbohydrate (% kcal)	70	20	20	20	20
Energy density (kcal/g)	3.82	5.21	5.21	5.21	5.21

Features of type 2 diabetes


- Glucose intolerance
- Elevation of blood glucose
- Elevation of blood insulin and leptin
- Increase of blood free fatty acids, cholesterol and triglycerides
- Decrease of blood adiponectin



Experimental design




Body weight




#Compared to HFC, $P < 0.0001$; ^{a,b}values labeled with different letters differ, $p < 0.05$


Food intake




Semi-fasting (4-6 hr) blood glucose





Oral glucose tolerance during week 8 of treatment





Area under the curve (AUC) of oral glucose tolerance





Fasting blood insulin and leptin



Fasting blood glucose (FBG) and total cholesterol



Homeostasis model assessment of insulin resistance (HOMA-IR) and β -cell function (HOMA- β)



Blood adiponectin and free fatty acid (FFA)

	LFC	HFC	HPH15	HPH35	HPH70
Serum adiponectin (ng/mL)	10.66 ± 0.31	9.79 ± 0.26 [#]	8.84 ± 0.36	9.95 ± 0.22	8.99 ± 0.40
FFA (mmol/mL)	0.13 ± 0.01	0.10 ± 0.01	0.12 ± 0.01	0.11 ± 0.01	0.09 ± 0.01

Take home message

HPH improves insulin resistance and glucose intolerance in DIO mice

The effect might be a result of lowering weight gain, improve pancreatic beta cell function and/or peripheral tissue insulin sensitivity

Further studies are warranted to determine the responsible components (protein, peptides, AAs, FAs, antioxidants, etc.) and the underlying mechanisms

Acknowledgements

Dr. Sandhya Nair
Dr. Moumita Roy
Ms. Shelly (Yu) Sha
Ms. Danica Albert
Dr. Ludovic Tripoteau
Mr. Claude Pelletier
Dr. Junzeng Zhang
Dr. Steve Ewart
Dr. Vanya Ewart



Funding Supports



National Research
Council Canada

Conseil national de
recherches Canada

Thank You

Contacts:

Yanwen Wang
Senior research officer
National Research Council of Canada
Charlottetown, PE, Canada C1A 4P3
Yanwen.wang@nrc.ca
(902) 566-7953

Jacques Gagnon,
Senior research scientist
VALORĒS
Shippagan, NB, Canada E8S 1J2
Jacques.gagnon@umoncton.ca
(506) 336-6600

Follow-up on herring milt

Business



Sébastien Haché
Director
www.valores.ca

Communication



Robert G. Landry
Coordinator
Communication & Marketing